Image Credit source: File Photo
In March this year, when the country started immunization of 12 to 14 year olds to protect against COVID-19, the Corbevax vaccine was used and its cost was fixed at Rs 145 for the government immunization programme.
Pharmaceutical Firm Biologicals E. Ltd. (Biological E Limited) said on Monday that it has developed its COVID-19 vaccine Corbevax (Corbevax) has been reduced from Rs 840 to Rs 250. Also this price includes GST. Due to this, end users will have to pay Rs 400 per dose including taxes and vaccination charges, the company said in a statement. Earlier private vaccination centers (private vaccination centers, The total cost for end users of the vaccine in the U.S. was Rs 990 per dose.
In March this year, when the country started immunization of children aged 12 to 14 to protect against COVID-19, the Corbevax vaccine was used and its price was fixed at Rs 145 for the government vaccination programme. Biologicals E Ltd. has manufactured 300 crore doses of Corbevax and has already supplied about 10 crore doses to the Central Government. More than 30 million doses of Corbevax have been administered to children between 12-14 years of age.
Demand to approve emergency use of Corbevax as a booster dose
A few days ago, Biological E had submitted an application to India’s drug regulator requesting emergency use approval to give Corbevax as a booster dose to adults who have taken either Covishield or both doses of Covaxin. The Drug Controller General of India had already approved the country-developed RBD protein subunit vaccine Corbevax for limited use in emergency situations for people aged five years and above. At present, it is being used for immunization of children in the age group of 12 to 14 in the country.
Based on drug regulatory approval as per EUA application submitted to DGCI, in a phase-3 clinical study, Biologicals E has evaluated the safety of Corbevax as a single dose booster in non-infected adults who have been fully vaccinated with CovShield or Covaccine . The study was conducted on 416 people aged 18 to 80 years who were given two doses of Covaxin or Covishield at least six months before a booster dose of Corbevax. An official source, citing the submission of the Hyderabad-based company in the EUA application, said that the results showed a significant increase in immunogenicity compared to Covishield and Covaccine in terms of neutralizing antibodies after 28 days. happened.
(with input language)
Source: www.tv9hindi.com
: Language Inputs
